Latest Conference Articles

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9th 2021, 7:38pm

International Myeloma Workshop

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021, 7:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

September 9th 2021, 7:07pm

IASLC World Conference on Lung Cancer

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

Data Confirms Efficacy of Fixed-Volume Isatuximab-Based Combination for Newly Diagnosed Multiple Myeloma

September 9th 2021, 7:03pm

International Myeloma Workshop

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021, 6:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9th 2021, 6:06pm

International Myeloma Workshop

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Daratumumab Plus Combination Therapy May Be New Standard of Care for Newly Diagnosed Multiple Myeloma

September 9th 2021, 5:59pm

International Myeloma Workshop

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

September 9th 2021, 5:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

September 9th 2021, 5:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Iberdomide Combination Shows Promise and Tolerability in Multiple Myeloma

September 9th 2021, 4:35pm

International Myeloma Workshop

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Phase 2 Data Signal a Potential Role for Neoadjuvant Osimertinib in EGFR-mutant NSCLC

September 9th 2021, 3:42pm

IASLC World Conference on Lung Cancer

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20 Insertion+ NSCLC Regardless of Prior Immunotherapy

September 9th 2021, 3:30pm

IASLC World Conference on Lung Cancer

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

September 8th 2021, 10:28pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC

September 8th 2021, 10:00pm

IASLC World Conference on Lung Cancer

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

Dr. Cortes on Emerging Therapies in CML

September 8th 2021, 9:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

Selpercatinib Elicits Durable Antitumor Activity in Advanced RET Fusion+ NSCLC

September 8th 2021, 8:52pm

IASLC World Conference on Lung Cancer

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Sotorasib Induces Intracranial Activity in KRAS G12C–Mutated NSCLC Brain Metastases

September 8th 2021, 7:55pm

IASLC World Conference on Lung Cancer

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma

September 8th 2021, 7:25pm

IASLC World Conference on Lung Cancer

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

September 8th 2021, 6:49pm

IASLC World Conference on Lung Cancer

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

September 8th 2021, 6:42pm

IASLC World Conference on Lung Cancer

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.